Sage Therapeutics Q3 2024 GAAP EPS $(1.53) Misses $(1.52) Estimate, Sales $11.871M Beat $10.802M Estimate
Sage Therapeutics Q3 2024 GAAP EPS $(1.53) Misses $(1.52) Estimate, Sales $11.871M Beat $10.802M Estimate
sage therapeutics 2024年第三季度的GAAP每股收益爲$(1.53)，低於$(1.52)的預估，銷售額爲1187.1萬美元，超過1080.2萬美元的預估
Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(1.53) per share which missed the analyst consensus estimate of $(1.52) by 0.66 percent. The company reported quarterly sales of $11.871 million which beat the analyst consensus estimate of $10.802 million by 9.89 percent. This is a 337.08 percent increase over sales of $2.716 million the same period last year.
sage therapeutics（納斯達克：SAGE）每股虧損$(1.53)，低於分析師一致預估的$(1.52)0.66%。公司報告的季度銷售額爲1187.1萬美元，超過分析師一致預估的1080.2萬美元9.89%。這是去年同期銷售額271.6萬美元的增長了337.08%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間